CombiMatrix Announces it Has Regained Compliance With Nasdaq Minimum
Stockholders' Equity Requirement
IRVINE, Calif., Aug. 21, 2013 (GLOBE NEWSWIRE) -- CombiMatrix Corporation
(Nasdaq:CBMX), a molecular diagnostics company specializing in DNA-based
testing services for developmental disorders and cancer diagnostics, today
announced that in a letter dated August 20, 2013, from the Director of Listing
Qualifications of The Nasdaq Stock Market LLC, the Company was informed that
it has regained compliance with Listing Rule 5550(b)(1) (the Rule), which
requires a minimum of $2.5 million stockholders' equity for The Nasdaq Capital
The letter from Nasdaq said that based on the Company's Form 10-Q for the
period ended June 30, 2013, which evidenced stockholders' equity of $5.7
million, the Nasdaq Staff has determined that CombiMatrix complies with the
Rule and "the matter is now closed."
There can be no assurance, however, that the Company will be able to maintain
compliance long-term with Nasdaq requirements for continued listing.
About CombiMatrix Corporation
CombiMatrix Corporation provides valuable molecular diagnostic solutions and
comprehensive clinical support for the highest quality of care – specializing
in miscarriage analysis, prenatal and pediatric healthcare. CombiMatrix offers
comprehensive testing services for the detection of genetic abnormalities at
the DNA level, beyond what can be identified through traditional
methodologies. The Company performs genetic testing utilizing advanced
technologies, including microarray, FISH, PCR and G-Band chromosome analyses.
Additional information about CombiMatrix is available at www.combimatrix.com
or by calling 1-800-710-0624.
CONTACT: Company Contact:
President & CEO, CombiMatrix Corporation
Tel (949) 753-0624
VP, Media Relations
Allen & Caron
Tel (949) 474-4300
Investor Relations Contact:
BPC Financial Marketing
Tel (800) 368-1217
Press spacebar to pause and continue. Press esc to stop.